Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
17:37:47 10/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.11 SEK | -0.09% |
|
+11.67% | +107.87% |
| 11-09 | Stockholm exchange rises slightly at open, Qliro surges on bid | FW |
| 11-09 | Stockholm bourse set to open slightly lower | FW |
| Market Cap | 5.17B 526M 470M 432M 392M 743M 49.32B 762M 2.06B 26.41B 1.98B 1.93B 83.17B | P/E 2026 * |
131x | P/E 2027 * | -43x |
|---|---|---|---|---|---|
| Enterprise Value | 4.24B 431M 385M 354M 322M 609M 40.43B 625M 1.69B 21.65B 1.62B 1.58B 68.18B | EV / Sales 2026 * |
37.5x | EV / Sales 2027 * | 8.69x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
London S.E.
| 0ABW | Delayed | |
|
CBOE
| Real-time | ||
|
OTC Markets
| PDPHF | Delayed | |
|
Boerse Muenchen
| P0F | Real-time | |
|
Börse Stuttgart
| P0F | Delayed | |
|
Deutsche Boerse AG
| P0F | Delayed | |
|
CBOE
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -0.09% | ||
| 1 week | +11.67% | ||
| Current month | +10.34% | ||
| 1 month | +11.56% | ||
| 3 months | +58.80% | ||
| 6 months | +65.18% | ||
| Current year | +107.87% |
| 1 week | 9.44 |  | 11.16 |
| 1 month | 8.96 | | 11.16 |
| Current year | 4.23 | | 11.16 |
| 1 year | 3.62 | | 11.16 |
| 3 years | 3.02 | | 11.16 |
| 5 years | 3 | | 11.16 |
| 10 years | 3 | | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 A | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 8/31/26 A | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 8/31/26 A | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.09% | +11.67% | +79.90% | +117.22% | 526M | |
| +2.24% | +8.40% | +58.47% | +69.00% | 68.22B | |
| +0.96% | +9.56% | +15.97% | +90.23% | 59.82B | |
| 0.00% | +1.17% | +23.56% | +97.19% | 56.07B | |
| -0.18% | +15.52% | +30.43% | +120.17% | 47.67B | |
| -1.37% | +7.89% | +32.49% | +45.30% | 45.95B | |
| -1.28% | +6.37% | +228.06% | +899.75% | 43.29B | |
| -0.47% | +9.38% | +27.53% | +52.40% | 35.66B | |
| -0.19% | -1.77% | +94.77% | +69.67% | 34.73B | |
| -0.03% | +6.21% | -38.80% | +395.73% | 25.47B | |
| Average | -0.02% | +7.91% | +55.24% | +195.66% | 42B | |
| Weighted average by Cap. | +0.18% | +7.84% | +53.68% | +183.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 11.5M 10.26M 9.44M 8.57M 16.24M 1.08B 16.64M 45.02M 577M 43.15M 42.22M 1.82B | 512M 52.11M 46.51M 42.8M 38.84M 73.61M 4.88B 75.44M 204M 2.61B 196M 191M 8.24B |
| Net income | 414M 42.14M 37.61M 34.61M 31.41M 59.53M 3.95B 61M 165M 2.11B 158M 155M 6.66B | -42.62M -4.34M -3.87M -3.56M -3.23M -6.13M -407M -6.28M -16.99M -218M -16.28M -15.93M -686M |
| Net Debt | -932M -94.86M -84.67M -77.91M -70.71M -134M -8.89B -137M -371M -4.76B -356M -348M -14.99B | -720M -73.29M -65.41M -60.19M -54.63M -104M -6.87B -106M -287M -3.68B -275M -269M -11.58B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | SEK 11.10 | -0.18% | 3,071,538 |
| 09/11/26 | SEK 11.12 | 0.00% | 4,571,816 |
| 06/11/26 | SEK 11.12 | 0.00% | 8,794,096 |
| 05/11/26 | SEK 11.12 | +11.31% | 33,332,869 |
| 04/11/26 | SEK 9.990 | +0.50% | 4,746,802 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
